ArticleBioorganic & medicinal chemistry letters2018
3-Hydroxy-1,5-dihydro-2H-pyrrol-2-ones as novel antibacterial scaffolds against methicillin-resistant Staphylococcus aureus.
Article in Bioorganic & medicinal chemistry letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Improved Library of Pyrrolidine-2,3-dione Monomers as Antimicrobial and Antibiofilm Agents againstACS medicinal chemistry letters · 2026Article
- DBU-Promoted Cascade Cyclization/Thiolation of β-Enamino Diketones to 5-Sulfenylated 3-Hydroxy-γ-lactams.The Journal of organic chemistry · 2026Article
- Unlocking the Potential of Pyrrole: Recent Advances in New Pyrrole-Containing Compounds with Antibacterial Potential.International journal of molecular sciences · 2024Review
- Pyrrolidine-2,3-diones: heterocyclic scaffolds that inhibit and eradicateChemical communications (Cambridge, England) · 2024Article
- Synthesis and computational evaluation of the antioxidant activity of pyrrolo[2,3-RSC advances · 2024Article
- Total Synthesis and Microbiological Evaluation of Leopolic Acid A and Analogues.ACS bio & med chem Au · 2024Article
- Synthetic Approaches to Novel Human Carbonic Anhydrase Isoform Inhibitors Based on Pyrrol-2-one Moiety.Journal of medicinal chemistry · 2024Article
- Expanded library of novel 2,3-pyrrolidinedione analogues exhibit anti-biofilm activity.Bioorganic & medicinal chemistry letters · 2024Article
- Synthesis and antibacterial activity of 2-benzylidene-3-oxobutanamide derivatives against resistant pathogens.RSC medicinal chemistry · 2023Article
- Synthesis and evaluation of the antioxidant activity of 3-pyrroline-2-ones: experimental and theoretical insights.RSC advances · 2022Article
- Experimental and theoretical studies on the synthesis of 1,4,5-trisubstituted pyrrolidine-2,3-diones.Beilstein journal of organic chemistry · 2022Article
- Amination of 5-Spiro-Substituted 3-Hydroxy-1,5-dihydro-2Molecules (Basel, Switzerland) · 2021Article
- Leveraging Marine Natural Products as a Platform to Tackle Bacterial Resistance and Persistence.Accounts of chemical research · 2021Article
- Stereoselective, Multicomponent Approach to Quaternary Substituted Hydroindole Scaffolds.Organic letters · 2020Article
- Potent trifluoromethoxy, trifluoromethylsulfonyl, trifluoromethylthio and pentafluorosulfanyl containing (1,3,4-oxadiazol-2-yl)benzamides against drug-resistant Gram-positive bacteria.RSC medicinal chemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Herein, we report the synthesis and evaluation of 3-hydroxy-1,5-dihydro-2H-pyrrol-2-ones as antibacterial agents against methicillin-resistant S. aureus (MRSA) and methicillin-resistant S. epidermidis (MRSE). Lead compound 38 showed minimum inhibitory concentrations (MICs) of 8 and 4 μg/mL against MRSA and MRSE, respectively. Furthermore, compound 38 displayed a MIC of 8-16 μg/mL against linezolid-resistant MRSA. These molecules, previously underexplored as antibacterial agents, serve as a new scaffold for antimicrobial development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.